Hodgkin lymphoma in patient with primary immunodeficiency: clinical features and treatment approaches
https://doi.org/10.17650/1818-8346-2022-17-3-73-82
Abstract
Primary immunodeficiencies (PID) are genetically determined irreversible disorders of structure and/or functions of the immune system's cellular and humoral components, accompanied by frequent infectious diseases and contributing to the development of malignant neoplasms. Lymphomas are the most frequent oncological disease in PID patients: non-Hodgkin's lymphomas occur in 60 % of malignant neoplasms cases, Hodgkin lymphoma - in 20 %, leukemias - in 10 %, solid tumors - in 10 %. The risk of malignant lymphoproliferative diseases in PID patients amounts to 4-25 %, with the overall incidence of cancer 100-200 times higher than in immunocompetent population. Results of malignant neoplasms treatment in children with PID remain unsatisfactory due to the high rate of relapsed, refractory disease and anticancer therapy complications.
This paper presents a clinical case of Hodgkin lymphoma with atypical localization in a female PID patient. peculiarities of this case are eye socket soft tissue involvement, slow response to therapy, and a high rate of infectious complications.
About the Authors
K. I. Utesheva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Kristina I. Utesheva.
24 Kashirskoe Shosse, Moscow 115478.
E. S. Belyaeva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
T. T. Valiev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478; Build. 2, 8 Trubetskaya St., Moscow 119991.
A. A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
References
1. Mueller B.U., Pizzo P.A. Cancer in children with primary or secondary immunodeficiencies. J Pediatr 1995;126(1):1-10.
2. Ochs H.D., Hitzig W.H. History of primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 2012;12(6):577-87. DOI: 10.1097/ACI.0b013e32835923a6
3. Tran H., Nourse J., Hall S. et al. Immunodeficiencyassociated lymphomas. Blood Rev 2008;22(5):261-81.
4. Ярилин А.А. Иммунология. М.: ГЭОТАР-Медиа, 2010. 749 с. [Yarilin A.A. Immunology. Moscow: GEOTAR-Media, 2010. 749 p. (In Russ.)].
5. Saar K., Chrzanowska K.H., Stumm M. et al. The gene for the ataxia-telangiectasia variant, Nijmegen breakage syndrome, aps to a 1-cM interval on chromosome 8q21. Am J Hum Genet 1997;60:605-10.
6. Deripapa E.V., Shvets O.A., Abramov D.S. et al. Analysis of the incidence of lymphomas in children with primary immunodeficiencies. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2016;15(1):61-5. (In Russ.). DOI: 10.24287/1726-17082016-15-1-61-65
7. Engel K., Rudelius M., Meinel F.G. et al. Cite this article as: Engel et al.: An adult patient with Nijmegen breakage syndrome and Hodgkin's lymphoma. BMC Hematology 2014;14(2):2. DOI: 10.1186/2052-1839-14-2
Review
For citations:
Utesheva K.I., Belyaeva E.S., Valiev T.T., Odzharova A.A. Hodgkin lymphoma in patient with primary immunodeficiency: clinical features and treatment approaches. Oncohematology. 2022;17(3):73-82. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-3-73-82
Views:
9421
Email this article 